These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 36383189)
41. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374 [TBL] [Abstract][Full Text] [Related]
42. Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception. Cohen MA; Edelman A; Paynter R; Henderson JT Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014908. PubMed ID: 36622724 [TBL] [Abstract][Full Text] [Related]
43. Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. Schrijver LH; Olsson H; Phillips KA; Terry MB; Goldgar DE; Kast K; Engel C; Mooij TM; Adlard J; Barrowdale D; Davidson R; Eeles R; Ellis S; Evans DG; Frost D; Izatt L; Porteous ME; Side LE; Walker L; Berthet P; Bonadona V; Leroux D; Mouret-Fourme E; Venat-Bouvet L; Buys SS; Southey MC; John EM; Chung WK; Daly MB; Bane A; van Asperen CJ; Gómez Garcia EB; Mourits MJE; van Os TAM; Roos-Blom MJ; Friedlander ML; McLachlan SA; Singer CF; Tan YY; Foretova L; Navratilova M; Gerdes AM; Caldes T; Simard J; Olah E; Jakubowska A; Arver B; Osorio A; Noguès C; Andrieu N; Easton DF; van Leeuwen FE; Hopper JL; Milne RL; Antoniou AC; Rookus MA; JNCI Cancer Spectr; 2018 Apr; 2(2):pky023. PubMed ID: 31360853 [TBL] [Abstract][Full Text] [Related]
44. Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception. Ramanadhan S; Hansen K; Henderson JT; Cohen MA; Paynter R; Edelman A Cochrane Database Syst Rev; 2023 May; 5(5):CD014908. PubMed ID: 37184292 [TBL] [Abstract][Full Text] [Related]
45. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know. Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561 [TBL] [Abstract][Full Text] [Related]
46. Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review. Krassuski L; Vennedey V; Stock S; Kautz-Freimuth S BMC Med Inform Decis Mak; 2019 Aug; 19(1):154. PubMed ID: 31370837 [TBL] [Abstract][Full Text] [Related]
47. Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland. Pallonen TA; Lempiäinen SMM; Joutsiniemi TK; Aaltonen RI; Pohjola PE; Kankuri-Tammilehto MK Sci Rep; 2022 Apr; 12(1):6704. PubMed ID: 35469032 [TBL] [Abstract][Full Text] [Related]
48. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Couch FJ; Gaudet MM; Antoniou AC; Ramus SJ; Kuchenbaecker KB; Soucy P; Beesley J; Chen X; Wang X; Kirchhoff T; McGuffog L; Barrowdale D; Lee A; Healey S; Sinilnikova OM; Andrulis IL; ; Ozcelik H; Mulligan AM; Thomassen M; Gerdes AM; Jensen UB; Skytte AB; Kruse TA; Caligo MA; von Wachenfeldt A; Barbany-Bustinza G; Loman N; Soller M; Ehrencrona H; Karlsson P; ; Nathanson KL; Rebbeck TR; Domchek SM; Jakubowska A; Lubinski J; Jaworska K; Durda K; Zlowocka E; Huzarski T; Byrski T; Gronwald J; Cybulski C; Górski B; Osorio A; Durán M; Tejada MI; Benitez J; Hamann U; Hogervorst FB; ; van Os TA; van Leeuwen FE; Meijers-Heijboer HE; Wijnen J; Blok MJ; Kets M; Hooning MJ; Oldenburg RA; Ausems MG; Peock S; Frost D; Ellis SD; Platte R; Fineberg E; Evans DG; Jacobs C; Eeles RA; Adlard J; Davidson R; Eccles DM; Cole T; Cook J; Paterson J; Brewer C; Douglas F; Hodgson SV; Morrison PJ; Walker L; Porteous ME; Kennedy MJ; Side LE; ; Bove B; Godwin AK; Stoppa-Lyonnet D; ; Fassy-Colcombet M; Castera L; Cornelis F; Mazoyer S; Léoné M; Boutry-Kryza N; Bressac-de Paillerets B; Caron O; Pujol P; Coupier I; Delnatte C; Akloul L; Lynch HT; Snyder CL; Buys SS; Daly MB; Terry M; Chung WK; John EM; Miron A; Southey MC; Hopper JL; Goldgar DE; Singer CF; Rappaport C; Tea MK; Fink-Retter A; Hansen TV; Nielsen FC; Arason A; Vijai J; Shah S; Sarrel K; Robson ME; Piedmonte M; Phillips K; Basil J; Rubinstein WS; Boggess J; Wakeley K; Ewart-Toland A; Montagna M; Agata S; Imyanitov EN; Isaacs C; Janavicius R; Lazaro C; Blanco I; Feliubadalo L; Brunet J; Gayther SA; Pharoah PP; Odunsi KO; Karlan BY; Walsh CS; Olah E; Teo SH; Ganz PA; Beattie MS; van Rensburg EJ; Dorfling CM; Diez O; Kwong A; Schmutzler RK; Wappenschmidt B; Engel C; Meindl A; Ditsch N; Arnold N; Heidemann S; Niederacher D; Preisler-Adams S; Gadzicki D; Varon-Mateeva R; Deissler H; Gehrig A; Sutter C; Kast K; Fiebig B; Heinritz W; Caldes T; de la Hoya M; Muranen TA; Nevanlinna H; Tischkowitz MD; Spurdle AB; Neuhausen SL; Ding YC; Lindor NM; Fredericksen Z; Pankratz VS; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Barile M; Bernard L; Viel A; Giannini G; Varesco L; Radice P; Greene MH; Mai PL; Easton DF; Chenevix-Trench G; ; Offit K; Simard J; Cancer Epidemiol Biomarkers Prev; 2012 Apr; 21(4):645-57. PubMed ID: 22351618 [TBL] [Abstract][Full Text] [Related]
50. Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer center. Assad H; Levitin M; Petrucelli N; Manning M; Thompson HS; Chen W; Jang H; Simon MS Breast Cancer Res Treat; 2024 Jul; 206(2):261-272. PubMed ID: 38605155 [TBL] [Abstract][Full Text] [Related]
51. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation. Vicus D; Finch A; Rosen B; Fan I; Bradley L; Cass I; Sun P; Karlan B; McLaughlin J; Narod SA; Gynecol Oncol; 2010 Aug; 118(2):155-9. PubMed ID: 20452659 [TBL] [Abstract][Full Text] [Related]
52. [GENOTYPE-PHENOTYPE CORRELATIONS BY SPECIFIC FOUNDER VARIANTS IN BRCA IN ISRAELI WOMEN]. Michaelson-Cohen R; Laitman Y; Kedar I; Baris-Feldman H; Reish O; Lieberman S; Bernstein-Molho R; Goldberg Y; Reznick Levi G; Gershoni R; Beller U; Levy-Lahad E; Catan R; Friedman E Harefuah; 2023 Jun; 162(6):370-375. PubMed ID: 37394440 [TBL] [Abstract][Full Text] [Related]
54. Difference in Risk of Breast and Ovarian Cancer According to Putative Functional Domain Regions in Korean BRCA1/2 Mutation Carriers. Park JS; Lee ST; Han JW; Kim TI; Nam EJ; Park HS Clin Breast Cancer; 2018 Oct; 18(5):362-373.e1. PubMed ID: 29673794 [TBL] [Abstract][Full Text] [Related]
55. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. Metcalfe K; Lubinski J; Lynch HT; Ghadirian P; Foulkes WD; Kim-Sing C; Neuhausen S; Tung N; Rosen B; Gronwald J; Ainsworth P; Sweet K; Eisen A; Sun P; Narod SA; J Natl Cancer Inst; 2010 Dec; 102(24):1874-8. PubMed ID: 21098759 [TBL] [Abstract][Full Text] [Related]
56. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589 [TBL] [Abstract][Full Text] [Related]
57. Specialty Care and Counselling about Hereditary Cancer Risk Improves Adherence to Cancer Screening and Prevention in Newfoundland and Labrador Patients with Roebothan A; Smith KN; Seal M; Etchegary H; Dawson L Curr Oncol; 2023 Oct; 30(10):9367-9381. PubMed ID: 37887578 [TBL] [Abstract][Full Text] [Related]
58. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. Modan B; Hartge P; Hirsh-Yechezkel G; Chetrit A; Lubin F; Beller U; Ben-Baruch G; Fishman A; Menczer J; Struewing JP; Tucker MA; Wacholder S; N Engl J Med; 2001 Jul; 345(4):235-40. PubMed ID: 11474660 [TBL] [Abstract][Full Text] [Related]
59. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1. Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ; J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670 [TBL] [Abstract][Full Text] [Related]
60. Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review. Huber D; Seitz S; Kast K; Emons G; Ortmann O J Cancer Res Clin Oncol; 2021 Jul; 147(7):2035-2045. PubMed ID: 33885953 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]